Herpetiform aphthous ulcerations induced by secukinumab: Report of 2 cases. by Benzaquen, Michael et al.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
8
3
3
2
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
CASE REPORTFrom the
Hospita
Funding s
Conflicts o
speake
receive
and No
Service
discloseHerpetiform aphthous ulcerations induced by
secukinumab: Report of 2 casesMichael Benzaquen, MD, Nikhil Yawalkar, MD, Laurence Feldmeyer, MD, PhD, Luca Borradori, MD, and
Christoph Schlapbach, MD, PhD
Bern, SwitzerlandKey words: acute gingivostomatitis; aphthous; herpetiform; interleukin-17 blocker; psoriasis; secukinumab.Abbreviations used:
HSV: Herpes simplex virus
IL: interleukinINTRODUCTION
The antieinterleukin (IL)-17A antibody secukinu-
mab is used for moderate-to-severe plaque psoriasis,
psoriatic arthritis, and ankylosing spondylitis. It has
an excellent safety profile and its side effects are well
described.1 Nevertheless, many patients treated with
secukinumab in real life are needed to detect
exceedingly rare side effects. Here, we report 2 cases
of acute gingivostomatitis that developed on intro-
duction of secukinumab.
CASE REPORT
A 35-year-old woman presented with an 8-year
history of SAPHO (synovitis, acne, pustulosis,
hyperostosis, osteomyelitis) syndrome. The patient
was treated with various regimens, including sala-
zopyrin, methotrexate, and infliximab with poor
control of her osteoarticular manifestations. She
was started on secukinumab, 300 mg (standard
dosing for plaque psoriasis). Five weeks later, after
the induction phase, the patient experienced a first
episode of painful gingivostomatitis. She had 2
recurrences 2 and 6 months later, respectively,
causing discomfort and weight loss and lasting
3 weeks. She had no other gastrointestinal symptoms
or signs. On examination, she presented with painful
herpetiform ulcerations of the soft palate, a white-
coated tongue, and swollen and erythematous
papillae (Fig 1, A). Histologic studies showed an
acanthotic epithelial mucosa with spongiosis, exocy-
tosis, and numerous neutrophils associated with a
dense lymphohistiocytic infiltrate (Fig 1, B). Periodic
acideSchiff staining was negative. Herpes simplex
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immunohistochemistry on the biopsy repeatedly
remained negative. Several mycologic cultures
excluded infections with Candida species. The
clinical evolution was favorable within 3 weeks
with betamethasone mouthwash and reduction of
the secukinumab dose to 150 mg.
A 37-year-old woman had a 14-year-history of
plaque psoriasis. Her personal and familial histories
were unremarkable, with no evidence of inflamma-
tory bowel diseases. She had been treated with
methotrexate, etanercept, and adalimumab, with
incomplete control of her psoriasis. Therefore,
treatment with secukinumab, 300 mg, was initiated.
At the end of the induction phase, she experienced a
painful stomatitis with swollen lips, herpetiform
ulcerations, and whitish deposits on the tongue
(Fig 2). There were no other gastrointestinal mani-
festations. Search of HSV1 and HSV2 infection by
polymerase chain reaction and mycologic cultures
for Candida species yielded negative results. The
lesions completely resolved within 3 weeks after
discontinuation of secukinumab and replacement
with ustekinumab.
Causality between secukinumab treatment and
gingivostomatitis in our patients was assessed using
the French method2 and yielded plausible causality
based on the chronological development, the recov-
ery after cessation of secukinumab, the exclusion ofCorrespondence to: Michael Benzaquen, MD, Department of
Dermatology, Inselspital - Bern University Hospital, CH-3010
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Fig 1. A, A 35-year-old woman presented with painful herpetiform ulcerations of the soft
palate, a white-coated tongue, and swollen and erythematous papillae. B, Histologic studies
show an acanthotic epithelial mucosa with spongiosis, exocytosis, and numerous neutrophils,
associated with a dense lympho-histiocytic infiltrate.
Fig 2. A 37-year-old woman presented with whitish deposits on the tongue (A), swollen lips,
and herpetiform ulcerations of the lips and gums (B).
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and the absence of other inflammatory disease.
DISCUSSION
In the literature, the occurrence of non-Candida
gingivostomatitis after IL-17 blockers is only anec-
dotally reported. Mouth ulcerations were seen in 2
patients in a phase-2 secukinumab trial, but noclinical details were provided.3 Further, a case of a
patient with spondylarthrosis who had recurrent oral
ulcers after secukinumab treatment developed in-
flammatory bowel disease 1 month after the start of
secukinumab.4 After the second injection of secuki-
numab, this patient experienced periodic occur-
rence of endobuccal aphthoid lesions, appearing 2
to 3 days after each injection. Finally, a case of severe
JAAD CASE REPORTS
VOLUME 6, NUMBER 10
Benzaquen et al 1109mucositis appearing 1 week after initiation of secu-
kinumabwas described in a 62-year-old man.5 In this
case, secukinumab discontinuation resulted in sub-
stantial improvement. In our 2 cases, clinical course
as well as extensive laboratory workup reasonably
ruled out other inflammatory diseases potentially
affecting the oral mucosa, such as lichen planus,
autoimmune bullous diseases, or erythema
multiforme.5
Why oral aphthous ulcers developed after secu-
kinumab used remains unclear. Secukinumab is
associated with the development of mucocutaneous
candidiasis, as the IL-17 pathway is crucial for
antifungal defense.6 Yet, IL-17 blockers may also
affect the oral microbiome in way that is not detect-
able by mycologic cultures and may thus favor the
development of an inflammatory stomatitis.
Taken together, acute herpetiform aphthous ul-
cerations may represent a rare complication of
secukinumab treatment. The clinical outcome is
favorable after reduction or cessation of secukinu-
mab. With increasing use of IL-17 blockers, cliniciansshould be familiar with this rare but striking and
bothersome side effect.
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